信達生物(01801.HK)將安維汀生物類似藥之美加商業化權益授權予Coherus
信達生物(01801.HK)公布,與Coherus BioSciences達成一項合作協議,將集團的安維汀(貝伐珠單抗)生物類似藥(IBI-305)在美國和加拿大的商業化權益授權給Coherus。Coherus計劃於今年底至明年初向美國食品藥品監督管理局遞交生物製品許可證申請,具體時間取決於FDA審批進展,並在獲批後開始商業化銷售。
根據該協議條款,Coherus將就IBI-305支付集團首付款、里程碑付款4,500萬美元。另外,基於IBI-305未來的銷售情況,Coherus還將支付集團雙位數百分比的銷售分成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.